{"id":10911,"date":"2023-12-06T22:32:00","date_gmt":"2023-12-06T14:32:00","guid":{"rendered":"https:\/\/flcube.com\/?p=10911"},"modified":"2024-11-02T22:34:38","modified_gmt":"2024-11-02T14:34:38","slug":"jj-forecasts-5-7-cagr-through-2030-driven-by-innovative-medicine-and-device-growth","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=10911","title":{"rendered":"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth"},"content":{"rendered":"\n

Johnson & Johnson (J&J; NYSE: JNJ<\/a>) has presented an update on its business strategy, pipeline, and financial outlook amidst the loss of exclusivity for its blockbuster immunosuppressant Stelara (ustekinumab) in the US. The company anticipates operational sales growth of 5% to 6% in 2024 and 3% or more in 2025, excluding its SARS-CoV-2 vaccine. J&J is also targeting a 5% to 7% compound annual growth rate (CAGR) between 2025 and 2030.<\/p>\n\n\n\n

The innovative medicine business is projected to expand by 5% to 7% between 2025 and 2030, propelled by over 20 product launches by the end of the period. This includes more than 15 potential blockbusters such as the immunomodulator JNJ-4804, antidepressants Spravato (esketamine), seltorexant, and aticaprant, along with over 10 assets capable of generating over USD 5 billion in revenue, including the immunosuppressant JNJ-2113 and cancer drugs Talvey (talquetamab) and Tecvayli (teclistamab).<\/p>\n\n\n\n

J&J’s medical devices unit is expected to mirror this growth rate through 2027, with high-growth markets in interventional cardiovascular, robotics, and digital sectors driving the expansion.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[65,16,20,150,149,858],"class_list":["post-10911","post","type-post","status-publish","format-standard","hentry","category-company","tag-auto-immune","tag-cancer","tag-finance","tag-jj","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"\nJ&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline, and financial outlook amidst the loss of exclusivity for its blockbuster immunosuppressant Stelara (ustekinumab) in the US. The company anticipates operational sales growth of 5% to 6% in 2024 and 3% or more in 2025, excluding its SARS-CoV-2 vaccine. J&J is also targeting a 5% to 7% compound annual growth rate (CAGR) between 2025 and 2030.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=10911\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=10911\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-06T14:32:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-02T14:34:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10911#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10911\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth\",\"datePublished\":\"2023-12-06T14:32:00+00:00\",\"dateModified\":\"2024-11-02T14:34:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10911\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Cancer\",\"Finance\",\"J&J\",\"Johnson & Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10911#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10911\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=10911\",\"name\":\"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-12-06T14:32:00+00:00\",\"dateModified\":\"2024-11-02T14:34:38+00:00\",\"description\":\"Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline, and financial outlook amidst the loss of exclusivity for its blockbuster immunosuppressant Stelara (ustekinumab) in the US. The company anticipates operational sales growth of 5% to 6% in 2024 and 3% or more in 2025, excluding its SARS-CoV-2 vaccine. J&J is also targeting a 5% to 7% compound annual growth rate (CAGR) between 2025 and 2030.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10911#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=10911\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=10911#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth - Insight, China's Pharmaceutical Industry","description":"Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline, and financial outlook amidst the loss of exclusivity for its blockbuster immunosuppressant Stelara (ustekinumab) in the US. The company anticipates operational sales growth of 5% to 6% in 2024 and 3% or more in 2025, excluding its SARS-CoV-2 vaccine. J&J is also targeting a 5% to 7% compound annual growth rate (CAGR) between 2025 and 2030.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=10911","og_locale":"en_US","og_type":"article","og_title":"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=10911","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-12-06T14:32:00+00:00","article_modified_time":"2024-11-02T14:34:38+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=10911#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=10911"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth","datePublished":"2023-12-06T14:32:00+00:00","dateModified":"2024-11-02T14:34:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=10911"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Cancer","Finance","J&J","Johnson & Johnson","NYSE: JNJ"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=10911#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=10911","url":"https:\/\/flcube.com\/?p=10911","name":"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-12-06T14:32:00+00:00","dateModified":"2024-11-02T14:34:38+00:00","description":"Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline, and financial outlook amidst the loss of exclusivity for its blockbuster immunosuppressant Stelara (ustekinumab) in the US. The company anticipates operational sales growth of 5% to 6% in 2024 and 3% or more in 2025, excluding its SARS-CoV-2 vaccine. J&J is also targeting a 5% to 7% compound annual growth rate (CAGR) between 2025 and 2030.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=10911#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=10911"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=10911#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10911"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10911\/revisions"}],"predecessor-version":[{"id":10912,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/10911\/revisions\/10912"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}